Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bhaswati Mukherjee

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Journal of Biopharmaceutical Statistics|September 6, 2012
A Bayesian approach for inference from a bridging study with binary outcomesMihir Gandhi, Bhaswati Mukherjee, Debjit Biswas
Lifetime Data Analysis|March 4, 2009
Accelerated test system strength models based on Birnbaum-Saunders distribution: a complete Bayesian analysis and comparisonS K Upadhyay, Bhaswati Mukherjee, Ashutosh Gupta
Diabetes, Obesity & Metabolism|November 25, 2020
A single-dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US- and European-approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetesChristoph Kapitza, Leszek Nosek, Wolfgang Schmider, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 12, 2021
Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime InsulinViral N Shah, Edward Franek, Karin Wernicke-Panten, et al.
Indian Journal of Endocrinology and Metabolism|October 3, 2022
Pharmacokinetic Similarity between Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 and Originator Insulin Aspart Mix 70/30 (NovoMix 30) in Indian Adults with Type 2 Diabetes: GEMELLI M SubstudyViswanathan Mohan, Wolfgang Schmider, Kiran P Singh, et al.
Journal of Pharmaceutical Sciences|December 15, 2022
In vitro Stability of Biosimilar Insulin Aspart SAR341402 in the Medtronic MiniMed Insulin PumpsMandy Mohnicke, Arnd Blecher, Kathrin Beichert, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 4, 2020
Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study DesignTadej Battelino, Zsolt Bosnyak, Thomas Danne, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 25, 2020
Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study DesignTadej Battelino, Zsolt Bosnyak, Thomas Danne, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 27, 2020
InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study DesignTadej Battelino, Zsolt Bosnyak, Thomas Danne, et al.
The British Journal of Dermatology|July 16, 2025
Efficacy and safety of Cinainu in pediatric alopecia areata: an international, double-blind, randomized, placebo-controlled, phase 2/3 trialUlrike Blume-Peytavi, Bianca Maria Piraccini, Pascal Reygagne, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Journal of Biopharmaceutical Statistics|September 6, 2012
A Bayesian approach for inference from a bridging study with binary outcomesMihir Gandhi, Bhaswati Mukherjee, Debjit Biswas
Lifetime Data Analysis|March 4, 2009
Accelerated test system strength models based on Birnbaum-Saunders distribution: a complete Bayesian analysis and comparisonS K Upadhyay, Bhaswati Mukherjee, Ashutosh Gupta
Diabetes, Obesity & Metabolism|November 25, 2020
A single-dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US- and European-approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetesChristoph Kapitza, Leszek Nosek, Wolfgang Schmider, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 12, 2021
Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime InsulinViral N Shah, Edward Franek, Karin Wernicke-Panten, et al.
Indian Journal of Endocrinology and Metabolism|October 3, 2022
Pharmacokinetic Similarity between Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 and Originator Insulin Aspart Mix 70/30 (NovoMix 30) in Indian Adults with Type 2 Diabetes: GEMELLI M SubstudyViswanathan Mohan, Wolfgang Schmider, Kiran P Singh, et al.
Journal of Pharmaceutical Sciences|December 15, 2022
In vitro Stability of Biosimilar Insulin Aspart SAR341402 in the Medtronic MiniMed Insulin PumpsMandy Mohnicke, Arnd Blecher, Kathrin Beichert, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 4, 2020
Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study DesignTadej Battelino, Zsolt Bosnyak, Thomas Danne, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 25, 2020
Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study DesignTadej Battelino, Zsolt Bosnyak, Thomas Danne, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 27, 2020
InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study DesignTadej Battelino, Zsolt Bosnyak, Thomas Danne, et al.
The British Journal of Dermatology|July 16, 2025
Efficacy and safety of Cinainu in pediatric alopecia areata: an international, double-blind, randomized, placebo-controlled, phase 2/3 trialUlrike Blume-Peytavi, Bianca Maria Piraccini, Pascal Reygagne, et al.
Pageof 2